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Summary
Melanoma central nervous system metastases are increasing, and the challenges presented by this 
patient population remain complex. In December 2015, the Melanoma Research Foundation and 
the Wistar Institute hosted the First Summit on Melanoma Central Nervous System (CNS) 
Metastases in Philadelphia, Pennsylvania. Here, we provide a review of the current status of the 
field of melanoma brain metastasis research; identify key challenges and opportunities for 
improving the outcomes in patients with melanoma brain metastases; and set a framework to 
optimize future research in this critical area.
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brain metastasis; leptomeningeal disease; tumor microenvironment; clinical trials; experimental 
models
Introduction: clinical features and outcomes of melanoma central nervous 
system (CNS) metastases
Metastases to the brain far outnumber primary brain tumors (Maher et al., 2009). The most 
common sources of brain metastases are lung cancer, breast cancer, and melanoma. While 
lung cancer and breast cancer are much more prevalent, melanoma has the highest risk of 
spread to the CNS among all common cancer types. Previous studies have demonstrated that 
40–60% of patients with metastatic melanoma develop brain metastases at some point in the 
course of their disease, and autopsy series identified CNS involvement in up to 80% of 
patients with metastatic melanoma (Glitza et al., 2016). Several previous large studies 
reported the median survival of ~4 months from the diagnosis of melanoma CNS metastases, 
and melanoma brain metastases (MBM) are a leading cause of death from this disease 
(Davies et al., 2011; Fife et al., 2004; Raizer et al., 2008; Sampson et al., 1998; Skibber et 
al., 1996).
Clinical features associated with shorter survival in patients with MBMs in previous studies 
included the presence of active non-CNS disease, >3 MBMs, poor performance status (PS), 
and leptomeningeal involvement (reviewed in Glitza et al., 2016). Notably, the 
overwhelming majority of studies reporting the incidence and outcomes of MBMs were 
conducted prior to the development of contemporary immunotherapies and BRAF/MEK-
targeted therapies that have dramatically improved the survival in patients with metastatic 
melanoma. As these treatments achieve higher response rates and increasingly durable 
control of non-CNS disease, it is possible that the incidence of MBMs will increase, similar 
to the trajectory of breast cancer therapies. Alternatively, depending on blood–brain barrier 
penetrance and other relevant factors, the incidence of MBMs might actually decrease. The 
CNS has been identified as a common first site of systemic treatment failure in patients with 
melanoma treated with FDA-approved targeted therapies, but has yet to be characterized in 
depth in patients treated with immunotherapies (Frenard et al., 2015; Kim et al., 2011a). In 
addition, it is probable that these new therapies will impact the outcomes in patients with 
MBM, based on the results from initial prospective clinical studies (Long et al., 2012; 
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Margolin et al., 2012). The increasing availability and use of stereotactic radiosurgery 
(SRS), which was relatively limited in several historical studies, provides further rationale to 
re-evaluate contemporary outcomes in patients with MBM. Notably, technological advances 
in SRS now make it feasible for many small brain metastases to be treated in a single 
session, which may impact the prognostic significance of MBM number.
Updating information about the prevalence and outcomes of CNS metastases will provide an 
important resource for both clinicians and patients fighting this disease. Perhaps more 
importantly, this information will further highlight the critical unmet clinical need for more 
clinical trials for patients with MBM. Over the last decade, many key randomized clinical 
trials were conducted that ultimately resulted in the approval by the US FDA of 10 new 
treatment regimens for patients with stage IV melanoma from 2011 to the end of 2015 
(Table 1; Chapman et al., 2011; Hauschild et al., 2012; Hodi et al., 2010; Larkin et al., 2015; 
Long et al., 2015; Ribas et al., 2015; Robert et al., 2015a, b, 2011; Weber et al., 2015). All of 
these landmark trials, which in total included over 6000 patients with metastatic melanoma, 
excluded the participation of patients with active MBMs, irrespective of size and number, 
given the presumption that the prognosis of MBM is uniformly dismal. Small 
nonrandomized trials testing several of these agents in patients with MBM were opened after 
those landmark studies completed accrual. These studies included 234 patients and thus 
represented only 4.1% of the patients enrolled in the trials (Di Giacomo et al., 2012; Long et 
al., 2012; Margolin et al., 2012). However, based at least in part on the promising clinical 
activity that was observed in those clinical trials, an increasing number of trials are now 
becoming available for metastatic melanoma patients with active brain metastases (Table 2). 
An improved understanding of the factors that are prognostic in contemporary MBM 
patients will be important for appropriately interpreting the results of those trials. Ultimately, 
the availability of such information will be critical to the appropriate design of future 
prospective randomized clinical trials in patients with MBM, which are clearly needed.
Improving outcomes in MBMs will also be accelerated by developing improved 
understanding of the pathophysiology and therapeutic resistance of these tumors. There is 
growing evidence in multiple tumor types, including melanoma, that while many molecular 
features can be shared, brain metastases often have key, distinct features compared with both 
primary tumors and metastases to other organs, even in the same patient (Brastianos et al., 
2015; Chen and Davies, 2012). These findings support the need for focused preclinical 
studies of MBMs to identify the critical factors and therapeutic targets for MBMs. Notably, 
existing data support the rationale to characterize both tumor cells and the unique tumor 
microenvironment (TME) of the CNS. In addition, and in parallel with the multidisciplinary 
clinical approach, there is strong rationale to incorporate multiple approaches to the study of 
MBMs, including but not limited to ‘omics’ (i.e., mutational, transcriptional, proteomic, 
epigenetic), immunology, and metabolism.
Clinical investigations
Targeted therapy
Temozolomide, a chemotherapy agent that crosses the blood–brain barrier (BBB), has been 
used frequently in patients with MBM for decades despite the clinical trials demonstrating 
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intracranial clinical response rates (ICRR) of 3–7% (Agarwala et al., 2004). Similar to the 
experience in patients without brain metastases, much more impressive results have been 
observed with BRAF inhibitors (BRAFi). The initial signal of CNS activity came from the 
phase I trial of dabrafenib, which included 10 patients with BRAFV600-mutant melanoma 
with untreated or progressing MBMs. Unconfirmed clinical responses were observed in 
eight patients, and the intracranial disease control rate (IDCR) was 100% (Falchook et al., 
2012). The subsequent BREAK-MB study, a phase II trial of dabrafenib in patients with 
MBM, remains to date the largest clinical trial conducted in this patient population (n = 
172). The trial included distinct cohorts of patients who had not received any previous local 
treatment for brain metastases and those with disease progression in the brain after surgery, 
whole-brain radiotherapy (WBRT), or SRS. Stable or tapering doses of corticosteroids were 
permitted. In patients with previously untreated MBMs, the ICRR was 39.2%, and the IDCR 
was 81.1%; the similar results were observed in patients with progressive MBMs after prior 
CNS surgery or radiation (ICRR 30.8%, IDCR 89.2%; Long et al., 2012). Median overall 
survival was 33.1 and 31.4 weeks for the two cohorts, respectively. Notably, neither trial 
required testing of tissue from the brain metastases for BRAF mutation testing, based on 
data supporting a very high concordance of BRAFV600 mutation status between brain 
metastases and other extracranial metastatic sites, a finding consistent with the clinical 
activity observed in the trial (Chen et al., 2014; Colombino et al., 2012). As initial 
preclinical studies indicated that dabrafenib did not cross the intact BBB significantly, the 
results also support that the BBB is compromised by brain metastases. A smaller phase II 
study of vemurafenib in melanoma patients with symptomatic brain metastases reported an 
ICRR of only 16.1% (Dummer et al., 2014). Treatment was generally well tolerated with 
rare cases of adverse events (neurologic or systemic) requiring discontinuation of the study 
drug. While there is some preclinical evidence to suggest that vemurafenib penetrates brain 
tissue less efficiently than dabrafenib (Mittapalli et al., 2013), the presence of neurologic 
symptoms has been identified as a negative prognostic factor in previous studies of patients 
with MBM, suggesting that this was a cohort of patients with particularly aggressive disease 
(Glitza et al., 2016). Additional retrospective studies also support a significant activity for 
vemurafenib in MBMs (Dzienis and Atkinson, 2014).
Randomized clinical trials in BRAFV600-mutant metastatic melanoma patients without CNS 
metastases demonstrated the superiority of combined BRAF and MEK inhibition to BRAFi 
monotherapy (Larkin et al., 2014; Long et al., 2015; Robert et al., 2015a). These results led 
to the regulatory approval of the dabrafenib + trametinib (D+T) regimen in 2014 and for 
vemurafenib + cobimetinib (V+C) in 2015. Clinical trials are currently ongoing to evaluate 
the safety and efficacy of each of these combinations in patients with previously untreated or 
progressing MBMs [NCT02039947 for D+T; NCT02537600 and NCT02230306 for V+C]. 
Dabrafenib is also being evaluated in combination with SRS [NCT01721603]. In addition to 
MAPK pathway inhibitors, a limited number of novel targeted therapies against other 
pathways are being explored in patients with MBM. Examples include a trial of abemaciclib 
(LY2835219, CDK4/6 inhibitor) for brain metastases from breast cancer, non-small-cell lung 
cancer (NSCLC), and melanoma [NCT 02308020], and a trial of buparlisib (BKM-120, pan-
PI3K inhibitor) specifically in patients with MBM [NCT02452294]. Abemaciclib penetrates 
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the BBB as does buparlisib (Koul et al., 2012; Raub et al., 2015). Other potential novel 
approaches include inhibitors of apoptosis, autophagy, and metabolism.
While MAPK pathway inhibitors achieve high rates of disease control in MBMs, the 
overwhelming majority of patients have short progression-free survival. In contrast to 
extracranial tumors, currently there is very limited understanding of the mechanisms of 
resistance to MAPK pathway inhibitors in MBMs. While it is very possible that the same 
alterations mediate resistance in MBMs as in extracranial tumors, there are also reasons to 
consider additional mechanisms. For example, analysis of biopsies collected in the phase I 
trial of vemurafenib demonstrated a linear relationship between the degree of MAPK 
pathway inhibition achieved and the amount of tumor regression observed (Bollag et al., 
2010). Subsequent studies have demonstrated that the approved doses of both vemurafenib 
and dabrafenib produce a marked (>90%) inhibition of MAPK pathway activation in 
biopsies of non-CNS metastases (Sosman et al., 2012). However, as many agents achieve 
significantly lower levels in the CSF and brain compared with the blood, it is possible that 
suboptimal MAPK pathway inhibition could cause the diminished activity in patients with 
MBM. At this time, there are no data available about the degree of MAPK pathway 
inhibition achieved in melanoma brain metastases with the approved doses of vemurafenib 
or dabrafenib, but ‘neoadjuvant’ or precraniotomy window trials in patients with surgically 
resectable MBMs could address this gap in understanding (i.e., NCT01978236). The 
tolerability of BRAF inhibitors, and particularly of BRAF/MEK combination regimens, 
supports the feasibility of evaluating higher doses in patients with MBM if suboptimal 
pathway inhibition is detected. Indeed, a case report in a patient with progressing brain 
metastases from NSCLC with an activating EGFR mutation demonstrated that increasing 
dosing of the EGFR inhibitor gefitinib above the standard levels achieved higher drug 
exposure in the CSF, along with radiographic and symptomatic improvement of CNS lesions 
(Jackman et al., 2006). Interestingly, DNA sequencing on progressing tumors collected at 
autopsy in that patient demonstrated the presence of a known resistance mutation in EGFR 
(T790M) in all sampled non-extracranial lesions, but it was not detected in the progressing 
CNS disease. Similar findings were demonstrated in a second NSCLC case report (Balak et 
al., 2006; Jackman et al., 2006).
In addition to pharmacodynamics, the differences in tumor biology and genetics could also 
contribute to resistance in MBMs. Whole-exome sequencing of brain metastases from 
patients with multiple tumor types, including a small number of melanomas, demonstrated 
that although the brain metastases and primary tumors share a common genetic ancestor, the 
brain metastases harbor additional oncogenic drivers not detected in the primary tumor 
(Brastianos et al., 2015). Somatic mutations affecting the CDK, MAPK, and the PI3K-AKT 
pathways were frequently detected in the brain metastases that were not detectable or that 
were only present in a small subpopulation of the DNA of the primaries. Two different 
melanoma-specific protein-based analyses, one using immunohistochemistry and the other 
using quantitative reverse-phase protein arrays (RPPA), also demonstrated evidence of 
increased activation of the PI3K-AKT pathway, but not in the MAPK pathway, in MBMs 
compared with extracranial metastases from the same patients (Chen et al., 2014; Niessner et 
al., 2013). Recent studies suggest that the PI3K-AKT pathway may be activated in tumor 
cells growing in the brain due to the transmission of microRNAs (miRNAs) that 
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downregulate PTEN expression by exosomes released by astrocytes in the tumor 
microenvironment (Niessner et al., 2013; Zhang et al., 2015). However, the loss of PTEN in 
patients with stage III melanoma has also been shown to correlate with significantly 
increased risk of MBM (Bucheit et al., 2014). Another recent study suggests that factors in 
the cerebrospinal fluid (CSF) may activate the PI3K-AKT pathway in melanoma cells 
(Seifert et al., 2016). Together, these findings, along with preclinical studies that 
demonstrated increased antitumor activity and survival (Chen et al., 2014; Niessner et al., 
2016; Seifert et al., 2016), support the rationale for clinical testing of combinatorial 
approaches targeting the PI3K-AKT and MAPK pathways in patients with MBM. Notably, 
recent data demonstrate that the loss of PTEN can promote resistance to immunotherapy as 
well, suggesting additional combinatorial approaches (Dong et al., 2013; Peng et al., 2016).
Immune therapy
Immune therapies have dramatically changed the treatment landscape for metastatic 
melanoma. Similar to the experience with targeted therapy, clinical trial results with 
contemporary immunotherapies are relatively limited (Hong et al., 2010) in MBMs as the 
CNS was thought to be a relatively immune-privileged site. Furthermore, immune 
checkpoint inhibitors are antibodies, and concerns about minimal antibody passage across 
the blood– brain barrier, much like experiences with monoclonal antibody therapies in other 
cancers metastatic to the brain, resulted in the initial exclusion of patients with active MBMs 
from all clinical trials. Finally, some patients with MBM require steroids to reduce 
perilesional edema, which might curtail T-cell activation by immune therapies.
Results thus far from early trials, however, support the potential for clinical activity in 
patients with MBM, albeit with some unique challenges. In a subset analysis of a phase II 
trial of ipilimumab in patients with advanced melanoma, five of 12 patients with untreated 
MBMs responded to therapy (Weber et al., 2009, 2011). This was the first report of immune 
checkpoint inhibitors for patients with active MBMs and it led to a phase II trial of 
ipilimumab specifically for patients with MBM, which accrued 72 patients with 
asymptomatic MBMs or patients requiring corticosteroids (Margolin et al., 2012). 
Intracranial disease control was seen in 24% of the first group and 10% of the group 
requiring steroids. An expanded access protocol of ipilimumab allowed patients with stable 
asymptomatic MBMs with similar results; one-year overall survival was 20% among 165 
patients with MBM (Heller et al., 2011). The Italian Network for Tumor Biotherapy (NIBIT) 
conducted a phase II trial of ipilimumab and a nitrosourea alkylating agent, fotemustine 
(NIBIT-M1). Partial responses or stable diseases were seen in 25%, while 25% had a 
complete response in the brain (Di Giacomo et al., 2012, 2015). This led to the ongoing 
NIBIT-M2 trial for patients with untreated MBMs comparing fotemustine monotherapy, 
fotemustine plus ipilimumab, and ipilimumab plus nivolumab [NCT02460068].
A phase II trial of pembrolizumab for patients with metastatic melanoma or NSCLC with 
untreated brain metastases is also ongoing [NCT02085070], and the preliminary results are 
published (Goldberg et al., 2016). In the melanoma cohort, four of the first 18 patients were 
not evaluable due to the rapid extracerebral progression or hemorrhage. Four achieved 
partial intracranial response (22% of all patients, 29% of evaluable patients), three had stable 
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disease, and seven had disease progression; two had mixed responses, and one had 
histologically demonstrated pseudoprogression (Cohen et al., 2016). Response in the body 
was largely concordant with the CNS and responses were prolonged. It remains critical to 
recognize the possible effects of immunotherapy on MBMs, such as worsening edema and 
pseudo-progression, in order to allow for the appropriate treatment and interpretation of 
response.
A number of current and planned trials for patients with MBM will test the combinations of 
immune checkpoint inhibitors, and combinations with radiation, including ipilimumab plus 
nivolumab versus nivolumab monotherapy [NCT02320058 and NCT02374242], and 
ipilimumab plus radiation [NCT01703507, NCT01950195, and NCT02097732]. Details of 
radiation studies are discussed below. Tumor infiltrating lymphocyte (TIL) therapy has been 
used in the MBM population, and CNS responses have been observed (Hong et al., 2010). 
However, patients with untreated or progressing MBMs are generally excluded from trials, 
as the time required to produce TIL may be unacceptable for such patients.
Despite the challenges noted in treating MBM patients with immune-based therapy, durable 
CNS responses can be achieved, similar to responses in extracerebral sites. While these 
results are very promising, randomized trials are still lacking.
Intrathecal therapy for leptomeningeal disease (LMD)
The prognosis for LMD is dismal with a median overall survival of 4–6 weeks (Davies et al., 
2011; Groves, 2011; Oechsle et al., 2010; Raizer et al., 2008). Treatment options are very 
limited due to the generally diffuse pattern of involvement, and these patients have been 
excluded from almost all clinical trials for patients with advanced melanoma (including 
those for patients with MBMs). There is minimal evidence of clinical benefit from any 
intervention, although there are case reports of individual patients achieving good outcomes 
with various therapies (Hottinger et al., 2011; Kim et al., 2015; Pape et al., 2012; Salmaggi 
et al., 2002; Schaefer et al., 2011; Wilgenhof and Neyns, 2014).
One unique approach for patients with LMD that has largely been explored in other cancers 
such as breast cancer and lymphoma is direct intrathecal (IT) administration of therapies 
(Perissinotti and Reeves, 2010). Small trials of patients with LMD treated with IT 
chemotherapy showed very little benefit (Pape et al., 2012; Segura et al., 2012). As approved 
BRAF and MEK inhibitors do not have intravenous formulations, there are no data about the 
safety and efficacy of IT administration of targeted therapies for melanoma. Initial 
evaluation of IT immunotherapies supports the IT approach. While minimal activity was 
observed with IT interferon alpha-2b (Chamberlain, 2002; Dorval et al., 1992), a report of 
43 melanoma patients with LMD treated with IT interleukin-2 (IT IL-2) demonstrated 1-, 2-, 
and 5-year survival rates of 36%, 26%, and 13%, respectively, with some patients surviving 
and receiving treatment for >10 yr (Glitza et al., 2015b). However, IT IL-2 was associated 
with significant toxicities related to an increased intracranial pressure. Case reports have 
documented individual patients treated with IT cytotoxic T cells and IT TILs in combination 
with IT IL-2 (Clemons-Miller et al., 2001; Glitza et al., 2015a; Papadopoulos et al., 2002; 
Shonka et al., 2014). This supports the feasibility of such treatments, and a prospective trial 
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to determine the safety and efficacy of IT TIL in patients with LMD was recently activated 
(NCT00338377).
Radiation therapy
Much of what is known of the efficacy of radiation in MBM is based on studies including 
multiple cancer types. What is clear from randomized trials about the management of brain 
metastases is that (i) surgical resection of a large single symptomatic brain metastasis in 
patients with good systemic control and good functional status results in better neurologic 
outcome and survival (9.2 versus 3.5 months, P = 0.01) than WBRT (Patchell et al., 1990) 
and (ii) surgical resection followed by WBRT results in better local control and survival than 
surgical resection alone (Patchell et al., 1998).
For multiple brain metastases, no single paradigm has demonstrated superiority with regard 
to survival. WBRT has therefore played a central role for decades in the treatment for 
MBMs. WBRT was reported to improve neurologic symptoms as early as the 1950s (Chao 
et al., 1954). While survival is not prolonged, a subset analysis of patients with symptomatic 
brain metastases showed that the clinical benefit is limited to this population. However, 
WBRT fails to provide the long-term disease control, as most patients develop recurrent 
brain metastases. In addition, melanoma is relatively radiation resistant; melanoma cells 
were shown in early in vitro studies to have a low responsiveness to radiation, which 
corresponded with the documented low efficacies of WBRT in clinical use (Fertil and 
Malaise, 1985). Patients with MBM who underwent WBRT in the early 2000s had a median 
survival of 3.4 months compared with 2.1 months if provided with supportive care (Davies 
et al., 2011; De La Fuente et al., 2014; Morris et al., 2004; Sampson et al., 1998). WBRT is 
therefore generally limited to MBM patients with no surgical options, symptomatic diffuse 
disease, large-volume single lesions, or LMD.
In contrast, SRS has emerged as a highly effective local therapy for MBM. Since studies 
performed by Patchell et al. (Patchell et al., 1990, 1998) in the 1990s, the overall 
management of brain metastases has changed significantly. Not only has there been 
recognition that screening for brain metastases using high-resolution MR imaging allows for 
the detection of small asymptomatic lesions that can be treated prior to the onset of 
symptoms, but also that treating small lesions minimizes the treatment risks and achieves 
better outcomes. Radiosurgery involves the treatment of individual brain metastases using 
single-fraction high-dose radiation while sparing the surrounding normal brain. The added 
value of WBRT to SRS is questionable; a randomized trial involving multiple tumor types 
showed that intracranial metastatic control following WBRT + SRS was not different than 
after SRS alone, and OS was equivalent (Andrews et al., 2004). Response of brain 
metastases was independent of cancer type, even for cancers previously designated 
radioresistant (Yaeh et al., 2015). A small study comparing WBRT alone to WBRT + SRS 
was stopped early due to a one-year local failure rate of 100% in those undergoing WBRT 
alone versus 89% in those undergoing WBRT + SRS (Kondziolka et al., 1999). SRS alone 
has therefore become the standard treatment for the majority of patients with limited MBMs. 
While there is still no prospective randomized MBM-specific study looking at SRS and its 
effect on survival, multiple single institution studies have demonstrated one-year intracranial 
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control rates of >80% and median survival of 5–11 months, with improved OS, especially 
for patients with controlled extracranial disease (Ajithkumar et al., 2015). Current 
recommendations are for use of SRS for patients with ≤ four brain metastases (single and 
oligometastatic disease) that are ≤3 cm in diameter. While many retrospective studies have 
also reported excellent outcomes following SRS for >4 lesions, no prospective or 
randomized trial data exist at this time (Flanigan et al., 2013). There are no studies of newer 
fractionated radiation techniques such as hippocampal sparing WBRT to preserve cognitive 
function in patients with MBM (Gondi et al., 2014). Similarly, no randomized studies exist 
comparing the outcome of WBRT consolidation versus SRS alone following the surgical 
resection of metastases, although retrospective series reports the favorable results using SRS 
alone for postoperative consolidation (Christ et al., 2015). Current radiosurgery delivery 
systems such as the Gamma Knife Perfexion are capable of treating multiple (i.e., >4) 
metastases in a single session, and patients can be treated repeatedly for new emerging 
metastases.
While there is strong rationale to combine treatment modalities, there are a paucity of 
prospectively generated data on the safety of combining WBRT or SRS with contemporary 
targeted and immune therapies for MBMs. Patients receiving radiation concurrently with 
vemurafenib have increased radiation-induced toxicity, and current practice is to interrupt 
BRAFi use during radiation therapy (Boussemart et al., 2013). A prospective study is 
ongoing to investigate the safety and activity of dabrafenib + SRS [NCT01721603]. One 
retrospective single institution review of patients with MBM treated with ipilimumab and 
SRS reported the improved outcomes compared with patients receiving SRS alone, but these 
findings were not corroborated by other retrospective single institution studies (Knisely et 
al., 2012; Mathew et al., 2013; Patel et al., 2015). It is currently unknown whether the 
improved control of CNS disease allows patients receiving immunotherapy to benefit 
maximally from immunotherapy or whether radiation-induced cell death results in an 
antitumor immune response that enhances immunotherapy (Postow et al., 2012). The safety 
and activity of ipilimumab and SRS or WBRT is being investigated (NCT02115139, 
NCT02097732, NCT02107755), and retrospective (Qian et al., 2016) and prospective 
studies of radiation and PD-1 inhibitors are underway.
CNS imaging and response assessment
Standardization of the neuroimaging protocol utilized in identifying and tracking brain 
metastases is of paramount importance to any clinical practice or experimental trial design. 
The current standard of care in imaging brain metastases relies on closed high-field 1.5- to 
4-Tesla MRI units. Open/low-field magnets are strongly discouraged due to their poor 
signal-to-noise resolution and therefore decreased lesion conspicuity. All follow-up lesion 
tracking should be performed at the same magnet field strength if possible, because 
metastases will be less conspicuous at lower field strengths. The type, dose (usually 0.1 
mmol/kg), and timing of the gadolinium-based contrast agent should be kept constant 
between studies. Single-dose gadolinium is preferred due to the concern for nephrogenic 
systemic fibrosis (NSF) in end-stage renal failure patients (Perez-Rodriguez et al., 2009; 
Prince et al., 2008) and the recent reports of gadolinium accumulation in patient’s brains 
after multiple MRI scans, which is of unknown significance (Kanda et al., 2014, 2015; 
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Mcdonald et al., 2015). The MR imaging protocol should utilize volumetric imaging 
techniques whenever possible with a maximum isotropic voxel size of 1.2 × 1.2 × 1.2 mm. 
2D sequences acquired should be performed at a maximum slice thickness of 5 mm with no 
gap. T2* gradient recall echo (GRE) or susceptibility weighted imaging (SWI) is 
recommended due to the high rate of hemorrhage in melanoma metastases. Interposing the 
T2-weighted sequences between contrast administration and the post-contrast T1-weighted 
sequences will increase the contrast delay time and therefore the enhancement of metastases. 
There is also supportive literature for acquiring the T2-weighted FLAIR sequence after 
contrast administration due to higher sensitivity for LMD than for T1W gradient or spin 
echo sequences (Fukuoka et al., 2010). Table 3 outlines the key sequences to be performed 
as part of any brain metastases imaging protocol. Specific parameters are not outlined due to 
the immense variability between MRI scanner hardware and software at individual 
institutions. Finally, it is well established in the literature and in practice that MRI is far 
more accurate and precise for assessing brain metastases than CT (Kanda et al., 2015; 
Mcdonald et al., 2015). CT should only be performed in the setting of an absolute MRI 
contraindication or in centers without MRI access. If performed, pre- and post-contrast CT 
should be collimated at 2.5 mm or less. Mixing modalities at different time points is strongly 
discouraged, as comparing metastases becomes highly inaccurate.
Until recently, there were no standardized response criteria or endpoints for clinical trials 
involving patients with brain metastases. Different studies have variably used one-
dimensional, two-dimensional, or volumetric measurements, and the specific thresholds for 
defining response and progression have also varied considerably between trials, making 
comparison very difficult. The International Response Assessment in Neuro-Oncology 
(RANO) Working Group has summarized the challenges in designing brain metastasis 
clinical trials (Lin et al., 2013a, b) and has recently proposed response criteria for brain 
metastases (RANO-BM; Lin et al., 2015). These criteria used one-dimensional 
measurements (RECIST) for assessing tumor response in both systemic tumors and brain 
metastases. However, the brain compartment is separated from the rest of the body, and 
clinical status and corticosteroid doses are taken into consideration. To address the effects of 
immunotherapies on tumor response, and the potential for the initial tumor flair, the RANO 
group recently published the iRANO criteria (Okada et al., 2015). These criteria suggest that 
patients ‘progressing’ in the first 6 months of immunotherapy, but clinically stable, should 
continue on therapy and have a repeat MRI to confirm the progression. Both the RANO-BM 
and iRANO criteria are being incorporated into brain metastases clinical trials and will 
require the prospective validation.
Trial design for CNS metastasis patients
The systemic drug development paradigm to date remains to establish the clinical safety and 
therapeutic efficacy in clinical trials designed for patients with extracerebral disease, 
excluding patients with brain involvement. Elucidating the specific pathways for melanoma 
brain metastasis and gaining further insights into the microenvironment and tumor–host 
interactions will lend support for the development of needed MBM-specific clinical trials. 
This is most significant for the development of drugs whose mechanism of action targets 
MBM-specific pathways. For example, historically, the use of a PI3K inhibitor would have 
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to be explored first in patients with extracerebral disease prior to patients with brain 
metastases. However, there are data to suggest that the PI3K pathway may be more 
important in cerebral than in extracerebral metastases, thus supporting the evaluation of 
inhibitors against this pathway specifically in the MBM patient population (Chen et al., 
2014; Davies et al., 2009; Seifert et al., 2016). An equally efficient approach is to allow the 
inclusion of melanoma brain metastases in clinical trials designed to bring the most 
promising therapies to patients with extracerebral metastases. As noted in the development 
of dabrafenib, phase I trials can systematically include a few patients with active melanoma 
brain metastases, perhaps in dedicated dose expansion cohorts, to provide an early safety 
and activity signal. A frequently cited challenge to include patients with MBM in later-phase 
studies in parallel with patients with extracerebral disease is their overall worse prognosis. 
However, this issue could be easily addressed in randomized settings where the presence of 
active untreated brain metastases in melanoma could be utilized as a stratification factor for 
number, and size of intracranial lesions as well as the presence/absence of neurologic 
symptoms, thereby isolating the impact of this population on the overall outcome of studies. 
Notably, the comparison of data from trials testing the same drug regimen in extracranial-
only versus active brain metastasis-specific disease setting supports that agents that 
demonstrate the efficacy in extracranial disease generally also show the activity in MBMs, 
lessening concerns about issues related to the penetration of the BBB (Azer et al., 2014; 
Goldberg et al., 2016; Margolin et al., 2012). Indeed, existing data support that brain 
metastases significantly compromise the BBB to a greater degree than primary brain tumors 
(Gerstner and Fine, 2007).
While there is a strong rationale to develop more clinical trials for patients with MBMs, such 
trials will be strengthened by attention to key aspects of their design. For example, 
standardization of the annotation of characteristics of patient with MBM in trials will 
facilitate meaningful comparisons of outcomes between studies. Consensus regarding key 
inclusion and exclusion criteria may also be helpful, particularly regarding the number and 
size of brain metastases and the use of prior radiation. Notably, the use of steroids is highly 
dependent on whether immunotherapy is utilized or not. Generally, steroids are not allowed 
at the time of initiation of immunotherapy based on the principle that they could inhibit early 
immune responses triggered by these agents.
Radiographic assessment of response of intracranial metastatic disease remains the most 
established primary endpoint for MBM trials, yet how these measurements should best be 
performed and interpreted remains controversial as discussed above (Quant and Wen, 2011). 
The ability to decrease the size of MBM may have a direct impact on the quality of life of 
patients, as even small changes in tumor size in critical areas of the brain might dramatically 
improve symptoms. Thus, response-related criteria are particularly meaningful in brain 
metastasis studies. However, standardization of response criteria is needed to facilitate the 
comparison between studies. The issue of standardization of response criteria is being 
addressed in part by the development of novel, brain-specific criteria such as RANO-BM 
and iRANO. Those approaches are critically needed, and the incorporation of the use of 
steroids into RANO-BM is a testament not only to the complexity of radiographic 
assessments in the brain, but also to the flexibility of response criteria to capture more 
realistically the clinical situation. Despite those efforts, there is an inherent variability in 
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MRI-based assessments related to multiple factors, including the high incidence of 
hemorrhage in MBM, the paramagnetic properties of melanin, and vasogenic edema, which 
can be induced both by tumor progression and by an immune response to therapy. Therefore, 
while radiographic endpoints may offer efficient primary endpoints for study designs, 
landmark survival endpoints should be considered to allow proper comparisons across 
clinical trials notwithstanding the mechanism of action of agents used (immune, targeted, or 
both). A meaningful and ‘hard’ endpoint is the one-year OS rate. This endpoint was very 
relevant in the development of the first wave of contemporary therapies. While it is quickly 
receding in favor of two-year OS with the advent of increasingly effective and durable 
therapies, one-year OS in the MBM population remains dismal and is a reasonable initial 
standard as we try to emulate the control of extracranial disease. Progression-free survival at 
6 months remains less than 50% in published studies and may represent another key 
benchmark, with the caveat that progression is still largely defined radiographically and thus 
will be subject to the challenges noted above. Other meaningful endpoints include time-to-
distant brain metastases failure, particularly in studies incorporating SRS in the treatment 
algorithm. Finally, the use of validated instruments of neurocognitive function and/or health-
related quality of life (HR-QoL) measures that have specifically been developed for patients 
with brain metastases, such as MDASI-BT and FACT-Br, will provide additional important 
information about the clinical impact of therapies for MBMs (Armstrong et al., 2006; 
Thavarajah et al., 2014).
Biology of brain metastases
Molecular determinants of brain metastases
An improved understanding of the pathogenesis of MBMs will facilitate the development 
and prioritization of rational therapeutic approaches for patients. There is growing evidence 
in multiple cancer types that brain metastases may harbor unique features. Such features 
may reflect advantages that support metastasis to the brain. As noted previously, one study 
of patients with stage III melanoma identified a strong association between the loss of 
expression of PTEN, which results in an increased activation of the PI3K-AKT pathway, and 
risk of MBM (Bucheit et al., 2014). This association is also supported by recent studies in 
genetically engineered mouse model, which will be described in more detail below (Cho et 
al., 2015). An integrated approach utilizing both cerebrotropic cell lines and clinical 
specimens identified PLEKHA5, a gene involved in brain development, as another possible 
promoter of cerebral metastasis (Jilaveanu et al., 2015). In vitro studies suggest that 
PLEKHA5 may promote transmigration across the BBB, while additional unpublished data 
indicate a possible interplay between PLEKHA5 and PI3K-AKT signaling.
Other possible links have been documented between PI3K pathway activation and 
expression or activity of a number of molecules previously implicated in brain metastasis, 
including vascular endothelial growth factor-A (VEGF-A), which causes BBB 
hyperpermeability and the rapid growth of MBMs; heparanase (HSPE), which enhances the 
invasiveness of melanoma cells to the brain; and connexins, which can mediate early events 
in brain metastasis, such as tumor cell extravasation and blood vessel co-option (Gingis-
Velitski et al., 2004; Huang et al., 2008; Kusters et al., 2002; Murry et al., 2006; Park et al., 
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2007; Vogt and Hart, 2011; Xie et al., 2006). In addition to the PI3K-AKT pathway, other 
studies support a role for JAK-STAT signaling to promote MBM, although an increased 
metastatic potential to other organ sites was also observed in those studies (Huang et al., 
2008; Xie et al., 2006). A retrospective study analyzing genome-wide and targeted miRNA 
expression profiling of primary melanoma tumors identified a miRNA-based signature to 
predict the development of brain metastasis (Hanniford et al., 2015). The expression of a 
group of four miRNAs in primary melanoma correlated with time to brain metastasis, and 
mechanistic studies are underway to further understand the basis of this correlation.
In addition to selective pressures, there is also evidence that the interactions of tumor cells 
within the TME of the brain may influence the pathogenesis and molecular biology of 
MBMs. Xenograft studies performed in mice demonstrated that implanting tumors cells in 
the brain results in reprogramming of a large (>1000) number of genes, regardless of the 
type of tumor cell that was implanted (Park et al., 2011). Gene expression patterns of brain 
metastases from different tumor types were more similar to each other than xenografts of the 
same tumor type growing in other metastatic sites. Interestingly, the gene expression pattern 
that characterized the brain metastases was similar to that seen in primary brain tumors. 
Many of these TME-induced gene network changes could be recapitulated in vitro by co-
culturing tumor cells with astrocytes, which also induced a marked resistance to 
chemotherapy (Kim et al., 2011b). In contrast, co-culturing of cancer cells with pulmonary 
fibroblasts had minimal effects. The interaction between the tumor cells and the astrocytes 
resulted in the increased production of the growth factor endothelin-1 (ET-1) by the 
astrocytes (Kim et al., 2014). Subsequent experiments showed that the treatment with a dual 
small-molecule inhibitor of endothelin receptor A and B markedly sensitized the tumor cells 
to chemotherapy, including in vivo models of breast and lung cancer brain metastasis (Lee et 
al., 2016). As noted previously, recent studies have also demonstrated that exosomes 
containing miRNAs released by astrocytes in the brain microenvironment cause 
downregulation of PTEN expression in breast cancer and melanoma brain metastases (Zhang 
et al., 2015). Recent data also suggest that the PI3K-AKT pathway may be activated in 
melanoma brain metastases by factors in the CSF (Seifert et al., 2016).
At this time, there are relatively limited data about the immunologic features of MBMs 
(Berghoff et al., 2015; Harter et al., 2015; Kluger et al., 2015). An IHC-based analysis of 
139 MBM craniotomy specimens from two academic institutions revealed that a high 
density of TILs and a low degree of intratumoral hemorrhage were associated with the 
prolonged overall survival. Furthermore, a high percentage of CD8+ effector T cells was a 
favorable prognostic factor, whereas the density of mature (CD31+/aSMA+), immature 
(CD31+/aSMA−), or sprouting (CD31+/Ang2+) blood vessels was neither prognostic nor 
associated with intratumoral hemorrhage. PD-L1, which could be an unfavorable prognostic 
marker, but may also be an important therapeutic target, was expressed not only in 
melanoma and immune cells, but also in reactive glial cells, suggesting that the brain tumor 
microenvironment is unique and actively contributes to local immunoregulatory 
mechanisms.
Together, these studies support the need for additional characterization of MBMs. 
Challenges to histopathologic assessment of craniotomy specimens are that only a 
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proportion of patients currently undergo craniotomies, unless the progress through 
noninvasive approaches, such as stereotactic radiosurgery and systemic treatments. This 
implies that less craniotomy specimens will come from untreated patients and more from 
patients who have received the prior treatment. Comparison of MBMs with other metastases, 
particularly from the same patients, will provide particularly important information about 
the shared and unique features of these tumors, which is critical to the development of 
rational therapeutic approaches. Building upon the studies described above, there is a 
rationale and need to evaluate other features of MBMs, such as metabolism and autophagy, 
which may identify the additional rational therapeutic strategies (Haq et al., 2013; Rebecca 
and Amaravadi, 2016). As noted in the discussion of clinical investigations, there is also a 
clear need to understand how contemporary therapies (targeted therapies, immunotherapies, 
radiation therapy) affect MBM biology. Due to the practical limitations of tissue acquisition 
from the CNS in the living subjects, the evaluation of noninvasive correlates of markers, 
including circulating markers in the blood or CSF, will likely facilitate translation and 
clinical application of discoveries. Another approach to overcome the limited tissue material 
in living subjects is to collect tumor specimens from patients with MBM shortly after death 
(warm autopsies).
Animal models of CNS metastasis
The development of more effective therapies for MBMs also critically depends upon the 
availability of clinically relevant models for functional testing. Several sophisticated mouse 
models of melanoma have recently been generated featuring relevant genetic alterations 
(Table 4; Mckinney and Holmen, 2011). While these models have provided a wealth of 
information, a major obstacle in studying MBM has been the lack of animal models that 
mimic the pattern of metastasis observed in human disease. To circumvent this limitation, 
several groups have employed experimental models in which human cells have been 
introduced into the brain via direct intracranial injection or into the CNS circulation via 
intracarotid or intracardiac injection (Gaziel-Sovran et al., 2013). Interestingly, data exist 
that melanoma cell lines may form different patterns of CNS metastases following such 
procedures. These models are useful for studying later stages of metastasis, but are limited in 
their ability to model earlier steps in the metastatic process. Such models have also been 
used for in vivo selection to isolate subclones with increased proclivity to establish brain 
metastases, which have been used to identify candidate features associated with MBM.
Xenograft animal models that could fully interrogate the development of MBMs would 
allow for testing of targeted agents that could prevent the development of CNS disease. 
Cruz-Munoz et al. (Cruz-Munoz et al., 2008) described a model engineered by subdermal 
injection of severe combined immune-deficient (SCID) mice with metastatic human 
melanoma cells. This model develops spontaneous brain metastases but with relatively long 
latency and low incidence. Recently, Cho et al. (Cho et al., 2015). demonstrated that the 
expression of activated AKT1 is sufficient to drive spontaneous lung and brain metastases in 
a non-metastatic autochthonous mouse model of melanoma driven by mutant BRAF and 
Ink4a/Arf loss. When also combined with PTEN loss, metastases developed with high 
penetrance after a relatively short latency and lung and brain metastases were observed in 
70% and 80% of the mice, respectively. This model not only allows further study into the 
Cohen et al. Page 14
Pigment Cell Melanoma Res. Author manuscript; available in PMC 2017 April 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
biology of melanoma metastasis but also enables testing of rational targeted strategies. In 
addition to these approaches, multiple laboratories have active programs to establish and 
propagate patient-derived xenografts (PDX). Data in other cancer types suggest that such 
models may reflect the molecular features of clinical disease better than the cell lines 
propagated in tissue culture. Investigations are underway in several laboratories to identify 
PDX models that can metastasize to the brain from subcutaneous tumors. Overall, these 
xenografts better recapitulate human MBM. However, currently, they do not allow studies of 
host immune response. Realizing the full potential of PDX models will require the 
development of humanized mice bearing patient-derived xenografts along with 
hematopoietic system reconstituted from CD34+ cells derived from the same patient to 
allow for interrogation of immunotherapeutic strategies in immunocompetent mouse 
(Werner-Klein et al., 2014). Notably, there also remains a largely unmet need to establish the 
robust models of LMD. Existing models generally utilize rats, not mice, and are generally 
technically challenging to establish, thus limiting their use by investigators (Cranmer et al., 
2005).
The zebrafish has emerged as a powerful preclinical model for melanoma due to its capacity 
for genetic manipulation, small-molecule screens, and in vivo imaging. Expression of either 
BRAFV600E or NRASQ61K under the mitf promoter leads to a 100% penetrant cutaneous 
melanoma in a p53−/− background. From these animals, Heilmann et al. (Heilmann et al., 
2015) developed green/red fluorescent protein (GFP/RFP)-tagged zebrafish melanoma cell 
lines, which can be transplanted into the optically transparent casper recipients. This allows 
for real-time in vivo imaging of metastatic progression at single-cell resolution. While the 
BRAFV600E model is characterized by a low rate of spontaneous brain metastases, brain 
metastases can be achieved through the direct implantation, suggesting that additional 
genetic, epigenetic, or microenvironmental factors can promote brain metastasis in the 
zebrafish. Efficient screening for such factors in an unbiased manner is a major strength of 
the zebrafish and can be achieved using genetic or small-molecule screening approaches. 
The zebrafish melanoma model is an ideal platform in which to discover candidate new 
pathways that can be validated in other models and therapeutically targeted.
Conclusions
Improving outcomes in melanoma CNS metastases: a path forward
To improve the outcomes for patients with MBM, both clinical and preclinical efforts 
focused on this disease population and the unique challenges posed by the CNS tumor 
microenvironment and associated toxicities are necessary. Key aspects of research and 
patient care include the following:
• Multidisciplinary care. Perhaps more than any other metastatic site, the clinical 
management of patients with MBMs requires multidisciplinary expertise and 
approaches. Collaborative teams optimally involve medical oncologists, 
neurosurgeons, neurooncologists, neuroradiologists, neuropathologists, and 
radiation oncologists to make treatment decisions and to evaluate and manage 
treatment responses and complications. Notably, as outcomes improve in patients 
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with MBM, there is a growing role/need for neurologists to evaluate the effects 
and sequelae of treatments on normal brain tissue and function/cognition.
• Clinical trials. Trials specifically tailored to this patient population are needed, 
and the inclusion of patients with MBM in clinical trials early in the drug 
development process will accelerate access to active therapies. This might 
include brain metastasis cohorts in early-phase trials of drugs that have 
preclinical activity in melanoma or brain metastasis-specific studies. While there 
are clearly overlapping molecular features in melanoma metastases to the brain 
compared with other sites, in which case brain metastasis cohorts on general 
melanoma trials is appropriate, it appears that certain pathways (i.e., PI3K) may 
be more activated in brain metastasis, and studies of pathways more activated in 
brain metastases might be tailored to patients whose disease course is driven by 
CNS lesions.
• Standardization of trial endpoints. As the number of clinical trials for this patient 
population increases, there is great need to standardize imaging response criteria 
and to tailor interventions (local and systemic) to different clinical settings based 
on the number, location, and size of brain metastases. Although trial design and 
eligibility criteria might differ depending on the intervention, standardized 
descriptions of patient characteristics and treatment outcomes will facilitate 
meaningful comparison between regimens prior to conducting randomized trials.
• Leptomeningeal disease. LMD remains a unique challenge. Inclusion of cohorts 
of patients with LMD in MBM trials, or separate trials for these patients, will be 
important moving forward. Clinical experience in melanoma and other cancers 
supports the rationale to evaluate intrathecal therapies in this population. There is 
also a need to develop preclinical models of LMD to expedite rational 
therapeutic development.
• Preclinical studies of the biology of melanoma brain metastases. Oncogenic 
pathways activated in brain metastases and extracerebral metastases frequently 
differ, as do the TME and immune response in the CNS. Basic science and 
functional preclinical studies focused specifically on brain metastases will likely 
result in further improvements in systemic therapies for this population. 
Continued development, and expansion of the repertoire, availability, and 
functional testing, of relevant preclinical models will be critical to future 
investigations and progress.
• Establishment of multi-institutional collaborative specimen banks. Given the 
practical limitations to obtaining high-quality clinical samples of MBMs, there is 
a strong rationale to support the pooling of MBM tissue resources among 
melanoma research centers. The availability of such a resource could accelerate 
research, validation, and discovery. The expansion of warm autopsy efforts may 
provide further important resources for MBM research, as will the evaluation of 
potential surrogates (i.e., blood, CSF) of the features of MBMs.
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• Collaborations with physicians and scientists working on other CNS tumors. 
Primary CNS tumors and brain metastases from other histologic types often 
share molecular and immune features with MBMs. Interdisciplinary 
collaborations may help to provide new insights into the key molecular and 
immunologic dependences of brain tumors, and expedite the development of 
more effective therapies.
Results from these concerted efforts will be presented at future workshops, with the ultimate 
goal of improving treatments and outcomes for melanoma patients with brain metastases.
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Table 1
Completed clinical trials in the melanoma brain metastases population
Pivotal phase III clinical trials excluding MBM MBM-specific phase II clinical trials
Study name n Study name n
Ipi + gp100   676 Ipi− CWG   72
Ipi + DTIC   502 BREAK-MB 172
BRIM-3   645 NIBIT-M1   20
BREAK-3   250
COMBI-v   704
COMBI-d   423
coBRIM   495
KEYNOTE-002   540
KEYNOTE-006   834
CheckMate-037   631
CheckMate-067   945
Total 6134 264
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Table 2
Active trials for patients with melanoma brain metastases
Active trials NCT
Targeted therapies
 Dabrafenib + Trametinib in BRAF-mutated patients NCT02039947
 Cobimetinib + Vemurafenib in BRAF-mutated patients NCT02537600
 Abemaciclib (LY2835219) NCT02308020
 Buparlisib (BKM-120) [BUMPER] NCT02452294
Immune therapies
 Pembrolizumab NCT02085070
 Nivolumab NCT02621515
 Ipilimumab + Nivolumab versus Nivolumab NCT02374242
 Ipilimumab + Nivolumab followed by Nivolumab monotherapy [Check Mate 204] NCT02320058
 Fotemustine versus Fotemustine + Ipilimumab versus Nivolumab + Ipilimumab NCT02460068
 Nivolumab + SRS NCT02716948
 Ipilimumab + SRS NCT02107755
 Ipilimumab + WBRT NCT02115139
[GEM STUDY]
 SRS followed by Ipilimumab versus SRS after Ipilimumab NCT02097732
 Lymphodepletion + Intrathecal adoptive cell transfer (for LMD) NCT00338377
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Table 4
Preclinical models of melanoma brain metastasis
Species Method Advantages Disadvantages
Mouse (Cruz-
Munoz et al., 
2008)
Syngeneic tumor model. 
Subcutaneous injection of 
murine melanoma cell 
lines, either from 
spontaneous melanomas 
or derived from GEM 
models. Primary tumor is 
resected and metastasis 
occurs spontaneously 
from the site of injection/
resection
• Recapitulates full metastatic 
cascade
• Can model the effects of key 
oncogenic events
• Preclinical adjuvant therapies 
may be tested
• Immunodeficient animals
• Cannot fully recapitulate 
molecular features of clinical 
disease (i.e., high mutation 
burden)
• Long latency between injection 
and metastasis
• Low metastasis incidence
• Limited preselected cell line 
availability
Mouse 
(Einarsdottir et 
al., 2014; 
Krepler et al., 
2016; Monsma 
et al., 2015)
Patient-derived 
xenografts. Primary or 
metastatic tumors 
(including MBMs) are 
transferred directly from 
the patient to the animal 
(generally 
subcutaneously)
• Conserves mutational profile 
and can reflect molecular 
diversity of these diseases
• Can recapitulate full 
metastatic cascade
• Adjuvant therapies may be 
tested
• Offer avenues toward 
personalized medicine; a 
potential for clinical 
prediction
• Immunodeficient animals
• Long latency between 
engraftment and metastasis 
from primary tumors
• Generally not injected 
orthotopically (but possible)
• Lacks broad availability
Mouse 
(Fujimaki et al., 
1996; Huang et 
al., 2008; Xie et 
al., 2006; Yano 
et al., 2000; 
Zhang et al., 
2009)
Intracarotid artery 
injection. Cells are 
directed to the brain via 
the internal carotid artery 
with limited cells entering 
the external carotid artery
• Permits cells to be delivered 
in a controlled manner
• Metastases develop quickly
• Numerous annotated cell 
lines available for use
• Fails to recapitulate the full 
metastatic cascade
• Technical challenges associated 
with microsurgery
• Rapid animal mortality 
following inoculation
Mouse (Izraely 
et al., 2012; 
Morsi et al., 
2013; 
Sundstrom et al., 
2013; Tekle et 
al., 2012)
Intracardiac injection. 
Cells are injected into the 
left ventricle of the heart, 
resulting in arterial 
distribution of cells 
throughout the animal
• Semi-high-throughput
• Pertinent stages of the brain 
metastatic process can be 
examined
• Brain metastases can develop 
in a reasonable time frame 
postinjection
• Fails to recapitulate the full 
metastatic cascade
• Frequent development of 
extracranial metastases
• Availability of preselected cell 
lines is scarce
Mouse 
(Umansky and 
Sevko, 2013)
Ret transgenic model. 
Mouse metallothionein I 
promoter/enhancer drives 
the expression of Ret 
kinase
• Immunocompetent animals
• Role of genetic abnormalities 
in tumor initiation and 
progression can be evaluated
• Clinical relevance, as Ret 
mutations are not observed in 
human melanoma
• Ability to model human disease 
is limited to corresponding 
transgene
Mouse (Cho et 
al., 2015)
Autochthonous model 
RCAS/TVA system. 
Metastases develop from 
the transformed 
indigenous melanocytes
• Immunocompetent animals
• Spatiotemporal gene transfer 
to somatic cells via tissue-
specific TVA expression
• Gene integration for the 
long-term expression
• Cell division is necessary for 
viral integration
• Random integration into host 
genome may influence the host 
gene expression
• Cannot fully recapitulate 
molecular features of clinical 
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Species Method Advantages Disadvantages
• Multiple genetic alterations 
can be investigated in a 
single animal
disease (i.e., high mutation 
burden)
Chicken (Busch 
et al., 2012)
Vesicle injection into the 
rhombencephalon of the 
brain.
Tumor nodules form, 
invade, and spread
• Embryo is easily accessible
• Transplants are not rejected
• Multiple cell lines may be 
used
• Unclear physiological relevance
• Limited to the examination of 
extravasation and invasion
Zebrafish 
(Heilmann et al., 
2015)
Fluorescently labeled cells 
can be injected into 
subcutaneous flank, 
directly into vasculature, 
or directly into brain
• Allows for high-resolution 
imaging, and thus evaluation 
of spatiotemporal dynamics 
of metastasis
• High-throughput
• can be easily assessed 
(genetic and small 
molecules)
• Metastatic process in embryo 
perturbed by growth-promoting 
effects of embryonic 
microenvironment
• Adult animal model 
immunocompromised
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